These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23607294)

  • 21. Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity.
    Kloth JK; Hillengass J; Listl K; Kilk K; Hielscher T; Landgren O; Delorme S; Goldschmidt H; Kauczor HU; Weber MA
    Int J Cancer; 2014 Nov; 135(10):2380-6. PubMed ID: 24706394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of the IL-6 receptor alpha-chain (CD126) in normal and abnormal plasma cells in monoclonal gammopathy of undetermined significance and smoldering myeloma.
    Salem DA; Korde N; Venzon DJ; Liewehr DJ; Maric I; Calvo KR; Braylan R; Tembhare PR; Yuan CM; Landgren CO; Stetler-Stevenson M
    Leuk Lymphoma; 2018 Jan; 59(1):178-186. PubMed ID: 28540748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
    Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
    Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).
    Sanoja-Flores L; Flores-Montero J; Garcés JJ; Paiva B; Puig N; García-Mateo A; García-Sánchez O; Corral-Mateos A; Burgos L; Blanco E; Hernández-Martín J; Pontes R; Díez-Campelo M; Millacoy P; Rodríguez-Otero P; Prosper F; Merino J; Vidriales MB; García-Sanz R; Romero A; Palomera L; Ríos-Tamayo R; Pérez-Andrés M; Blanco JF; González M; van Dongen JJM; Durie B; Mateos MV; San-Miguel J; Orfao A;
    Blood Cancer J; 2018 Nov; 8(12):117. PubMed ID: 30455467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HGF and IGF-1 synergize with SDF-1α in promoting migration of myeloma cells by cooperative activation of p21-activated kinase.
    Rø TB; Holien T; Fagerli UM; Hov H; Misund K; Waage A; Sundan A; Holt RU; Børset M
    Exp Hematol; 2013 Jul; 41(7):646-55. PubMed ID: 23499762
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STAT3 is over-activated within CD163
    Andersen MN; Andersen NF; Lauridsen KL; Etzerodt A; Sorensen BS; Abildgaard N; Plesner T; Hokland M; Møller HJ
    Cancer Immunol Immunother; 2022 Jan; 71(1):177-187. PubMed ID: 34061243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?
    Sidiqi MH; Aljama M; Kumar SK; Jevremovic D; Buadi FK; Warsame R; Lacy MQ; Dingli D; Gonsalves WI; Fonder AL; Hobbs MA; Hwa YL; Kapoor P; Kourelis T; Leung N; Muchtar E; Lust JA; Kyle RA; Go RS; Rajkumar VS; Gertz MA; Dispenzieri A
    Blood Cancer J; 2020 May; 10(5):52. PubMed ID: 32376870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. c-Met signaling promotes IL-6-induced myeloma cell proliferation.
    Hov H; Tian E; Holien T; Holt RU; Våtsveen TK; Fagerli UM; Waage A; Børset M; Sundan A
    Eur J Haematol; 2009 Apr; 82(4):277-87. PubMed ID: 19187270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Plasma Levels of the Angiogenic Cytokine Endocan Are Elevated in Patients with Multiple Myeloma.
    Steiner N; Hajek R; Sevcikova S; Borjan B; Untergasser G; Göbel G; Gunsilius E
    Anticancer Res; 2018 Sep; 38(9):5087-5092. PubMed ID: 30194153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contributions of the Bone Microenvironment to Monoclonal Gammopathy of Undetermined Significance Pathogenesis.
    Gámez B; Edwards CM
    Curr Osteoporos Rep; 2018 Dec; 16(6):635-641. PubMed ID: 30229522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of hepatocyte growth factor, platelet-derived growth factor-AB, and transforming growth factor-alpha in bone marrow and peripheral blood of patients with multiple myeloma.
    Kara IO; Sahin B; Gunesacar R; Unsal C
    Adv Ther; 2006; 23(4):635-45. PubMed ID: 17050506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myeloma-derived extracellular vesicles mediate HGF/c-Met signaling in osteoblast-like cells.
    Strømme O; Psonka-Antonczyk KM; Stokke BT; Sundan A; Arum CJ; Brede G
    Exp Cell Res; 2019 Oct; 383(1):111490. PubMed ID: 31283912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
    Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
    Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells.
    Tsubaki M; Seki S; Takeda T; Chihara A; Arai Y; Morii Y; Imano M; Satou T; Shimomura K; Nishida S
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
    Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
    Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells.
    Mylin AK; Rasmussen T; Johansen JS; Knudsen LM; Nørgaard PH; Lenhoff S; Dahl IM; Johnsen HE;
    Eur J Haematol; 2006 Nov; 77(5):416-24. PubMed ID: 16930142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma.
    Pilarski LM; Szczepek AJ; Belch AR
    Blood; 1997 Nov; 90(9):3751-9. PubMed ID: 9345062
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.